scholarly journals Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option

2016 ◽  
Vol 9 (2) ◽  
pp. 63-65 ◽  
Author(s):  
Jan-Paul Bohn ◽  
Guenther Gastl ◽  
Michael Steurer
Keyword(s):  
Hairy Cell Leukemia ◽  
Therapeutic Option ◽  
Term Treatment ◽  
Interferon Α ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Treatment

scholarly journals Long-term Treatment Outcome of Patients with Hairy Cell Leukemia: A Single-Center Experience

2018 ◽  
Vol 38 (3) ◽  
pp. 236-240
Author(s):  
Nergiz ERKUT ◽  
Derya SELİM BATUR ◽  
Osman AKIDAN ◽  
Volkan KARABACAK ◽  
Mehmet SÖNMEZ
Keyword(s):  
Treatment Outcome ◽  
Hairy Cell Leukemia ◽  
Term Treatment ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Single Center ◽  
Single Center Experience ◽  
Long Term Treatment

Tumorous manifestation of hairy cell leukemia after long-term treatment with interferon alpha

1995 ◽  
Vol 70 (2) ◽  
pp. 103-105
Author(s):  
S. Serke ◽  
D. Kaiser ◽  
A. Schmitt-Gr�ff ◽  
H. Stein ◽  
D. Huhn ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Term Treatment ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Treatment

Tumorous manifestation of hairy cell leukemia after long-term treatment with interferon alpha

1995 ◽  
Vol 70 (2) ◽  
pp. 103-105 ◽  
Author(s):  
D. Huhn ◽  
J. Oertel ◽  
S. Serke ◽  
D. Kaiser ◽  
A. Schmitt-Gräff ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Term Treatment ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Treatment

scholarly journals Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Robert J. Kreitman ◽  
◽  
Claire Dearden ◽  
Pier Luigi Zinzani ◽  
Julio Delgado ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Residual Disease ◽  
Braf Inhibitor ◽  
Nucleoside Analogs ◽  
High Rate ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Follow Up

Abstract Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL). Methods Eligible patients had received ≥ 2 prior systemic therapies, including ≥ 2 purine nucleoside analogs (PNAs), or ≥ 1 PNA followed by rituximab or a BRAF inhibitor. Patients received 40 µg/kg moxetumomab pasudotox intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles. Disease response and minimal residual disease (MRD) status were determined by blinded independent central review. The primary endpoint was durable complete response (CR), defined as achieving CR with hematologic remission (HR, blood counts for CR) lasting > 180 days. Results Eighty adult patients were treated with moxetumomab pasudotox and 63% completed six cycles. Patients had received a median of three lines of prior systemic therapy; 49% were PNA-refractory, and 38% were unfit for PNA retreatment. At a median follow-up of 24.6 months, the durable CR rate (CR with HR > 180 days) was 36% (29 patients; 95% confidence interval: 26–48%); CR with HR ≥ 360 days was 33%, and overall CR was 41%. Twenty-seven complete responders (82%) were MRD-negative (34% of all patients). CR lasting ≥ 60 months was 61%, and the median progression-free survival without the loss of HR was 71.7 months. Hemolytic uremic and capillary leak syndromes were each reported in ≤ 10% of patients, and ≤ 5% had grade 3–4 events; these events were generally reversible. No treatment-related deaths were reported. Conclusions Moxetumomab pasudotox resulted in a high rate of durable responses and MRD negativity in heavily pre-treated patients with HCL, with a manageable safety profile. Thus, it represents a new and viable treatment option for patients with R/R HCL, who currently lack adequate therapy. Trial registration ClinicalTrials.gov identifier: NCT01829711; first submitted: April 9, 2013. https://clinicaltrials.gov/ct2/show/NCT01829711

scholarly journals Hairy Cell Leukemia: Long Term Response to Cladribine

2018 ◽  
Vol 18 ◽  
pp. S280
Author(s):  
Anup Devasia ◽  
Anu Korula ◽  
Uday Kulkarni ◽  
Fouzia NA ◽  
Aby Abraham ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Response

scholarly journals Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience

Blood ◽  
1996 ◽  
Vol 88 (6) ◽  
pp. 1954-1959 ◽  
Author(s):  
MS Tallman ◽  
D Hakimian ◽  
AW Rademaker ◽  
C Zanzig ◽  
E Wollins ◽  
...  
Keyword(s):  
Relapse Rate ◽  
Hairy Cell Leukemia ◽  
Progression Free Survival ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Prior Therapy ◽  
Long Term Follow Up

Although 2-chlorodeoxyadenosine (2-CdA) is effective in inducing complete remissions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse rate, the clinical factors that may predict relapse, the long-term outcome, nor the response rate to re-treatment at relapse has been clearly determined. Fifty-two consecutive patients with previously untreated or treated HCL were treated with 2-CdA at a dose of 0.1 mg/kg/d by continuous intravenous infusion for 7 days. Of 50 assessable patients, 40 (80%) achieved CR, and 9 (18%) achieved partial remission (PR). A total of 7 patients (14%) have relapsed, at a median duration of 24 months (range, 12 to 44). Of the 7 relapsed patients, 5 were re-treated with a second cycle of 2-CdA; 2 achieved a second CR and 3 attained a PR. The progression- free survival (PFS) rate is 72% at 4 years for all 52 patients and 83% for patients achieving CR. The overall survival (OS) rate is 86% at 4 years. Only prior therapy was predictive of relapse. The majority of patients achieve durable CRs with a single cycle of 2-CdA. The relapse rate is low and the long-term prognosis is excellent. The few patients who relapse can attain second remissions after re-treatment with 2-CdA.

Sign in / Sign up

Export Citation Format

Share Document